Dergiler / Retina-Vitreus / 2014 / Cilt: 22 - Sayı: 2

Effects of initial intravitreal bevacizumab (Avastin) prior to laser photocoagulation in threshold ROP

Sayfa
93–98
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Conclusions: Bevacizumab 0.625 mg / 0.05 ml is a useful adjunct in posterior zone 1,2 ROP when followed by scatter laser photocoagulation.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Purpose: Threshold zone 1 and 2 ROP is a progressive disease with vision threatening complications.
📊
Temel Bulgular & Veri:In this cohort, we could achieve retinal stabilization when 0.625mg/ 0.05 ml injection was performed 3-4 days prior to retinal ablation.
💡
Sonuç & Katkı:Conclusions: Bevacizumab 0.625 mg / 0.05 ml is a useful adjunct in posterior zone 1,2 ROP when followed by scatter laser photocoagulation.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Purpose: Threshold zone 1 and 2 ROP is a progressive disease with vision threatening complications. In this cohort, we could achieve retinal stabilization when 0.625mg/ 0.05 ml injection was performed 3-4 days prior to retinal ablation. Material and Methods: Fourteen eyes received intravitreal bevacizumab. Inclusion criteria was zone 1,2 disease, stage 3, or 4 disease with plus disease. Four days later, laser PRP was given in a scatter pattern to the retinal periphery. Mean gestational age was 30 weeks, mean birth weight was 1279 gms, mean incubation period was 36 days and oxygen delivery for 15 days. Results: 11 eyes achieved retinal stabilization. Three eyes progressed to progressive tractional retinal detachment. One eye was successfully reposited by lens-sparing vitrectomy, one eye failed surgery and one eye was not operated. No systemic toxicity was observed from bevacizumab injection. Conclusions: Bevacizumab 0.625 mg / 0.05 ml is a useful adjunct in posterior zone 1,2 ROP when followed by scatter laser photocoagulation.

🔖

Bu Makaleye Atıf Yap

OTHMAN, I. S., SABRY, M., SADEK, S. H., REDA, A. (2014). Effects of initial intravitreal bevacizumab (Avastin) prior to laser photocoagulation in threshold ROP. Retina-Vitreus, Cilt: 22 - Sayı: 2, 93–98. https://ajindex.com/articles/305034

Kaynakça (14)

  1. El-Zanaty F and Way A. Egypt demographic and health sur- vey 2008. Calverton, Maryland (USA): Ministry of health and population (Egypt), National population Council and ORC Macro 2009:136
  2. Gilbert C, Rahi J, Eckstein M, et al. Retinopathy of prematu- rity in middle-income countries. Lancet 1997;350:12-4
  3. Hughes S, Yang H, Chan-Ling T. Vascularization of the hu- man fetal retina: roles of vasculogenesis and angiogenesis. Invest Ophthalmol Vis Sci 2000;41:1217-28
  4. Holmes DI, Zachary I. The vascular endothelial growth fac- tor (VEGF) family: angiogenic factors in health and disease. Genome Biol 2005;6:209
  5. Ferrara N, Gerber HP, Le Couter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669-76
  6. Sonmez K, Denser KA, Kapone A, et al. Vitreous levels of stromal cell-derived factor 1 and vascular endothelial growth factor in patients with retinopathy of prematurity. Ophthal- mology 2008;115:1065-70
  7. Travassos A, Teixeira S, Ferreira P, et al. Intravitreal beva- cizumab in aggressive posterior retinopathy of prematurity. Ophthalmic Surg Lasers Imaging 2007;38:233-7
  8. Chung EJ, Kim JH, Ahn HS, et al. Combination of laser pho- tocoagulation and intravitreal bevacizumab (Avastin) for ag- gressive zone I retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 2007;245:1727-30
  9. Honda S, Hirabayashi H, Tsukahara Y, et al. Acute contrac- tion of the proliferative membrane after an intravitreal injec- tion of bevacizumab for advanced retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 2008;246:1061-3
  10. Kong L, Mintz-Hittner HA, Penland RL, et al. Intravitreous bevacizumab as anti-vascular endothelial growth factor ther- apy for retinopathy of prematurity: a morphologic study. Arch Ophthalmol 2008;126:1161-3
  11. Shah PK, Narendran V, Tawansy KA, et al. Intravitreal beva- cizumab (Avastin) for post-laser anterior segment ischemia in aggressive posterior retinopathy of prematurity. Indian J Ophthalmol 2007;55:75-6
  12. Lalwani GA, Berrocal AM, Murray TG, et al. Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity. Retina 2008;28:13-8
  13. Ozdek S, Unlu M, Gurelik G, et al. Intravitreal anti-VEGF therapy as an adjunct to laser photocoagulation for APROP. J Optometry 2013;6:51-9
  14. Kusaka S, Shima C, Wada K, et al. Efficacy of intravitreal in- jection of bevacizumab for severe retinopathy of prematurity: a pilot study. Br J Ophthalmol 2008;92:1450-5. 1